A trial conducted internationally found that an anti-retroviral once-a-day pill works better at suppressing HIV in children. The treatment is also affordable and easy to take. The study tagged ODYSSEY was conducted by the University College of London.
According to Dr. Diana Gibb, an epidemiology professor at the university and a principal investigator of the ODYSSEY trial, their findings revealed strong evidence for the global rollout of dolutegravir for children living with HIV. She said medical treatments for HIV in children often lag behind adults because they need different formulations and studies.
Gibb added that the data from ODYSSEY, obtained from simplified dosing, reduced the treatment gap, and she and her team hope that countries can scale up children’s access to treatment globally. Dolutegravir-based regimens are already used to treat adults. In three to 18-year-olds, it reduced the odds of treatment failure by 40% compared to standard treatments.
While the international community seems to progress in HIV treatment and prevention, the United States is also charging ahead. Before Christmas, the Food and Drugs Administration (FDA) approved an injectable formulation of the HIV drug, Cabotegravir, for PrEP. Those highly likely to contract HIV will receive the injection every two months.
The new medicine is more long-lasting and discreet than the previously approved drugs. The preceding is supported by data from the HIV Prevention Trials Network (HPTN) research. The drug will be marketed under the brand name, Aperture, and its potentials are enormous.
Amid all these advancements, the PrEP drug, Truvada, continues to fend off lawsuits from users affected by its severe adverse effects. You, too, can still file a suit if this is your story.
Contact our mass tort lawyers at Dalimonte, Rueb, Stoller, LLP today for help.